Literature DB >> 7929417

Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding.

D A Brown1, S H Kang, S M Gryaznov, L DeDionisio, O Heidenreich, S Sullivan, X Xu, M I Nerenberg.   

Abstract

Phosphorothioate modification of internucleoside linkages is widely used to prevent degradation of oligodeoxynucleotide (ODN) therapeutic agents in serum and cells. This modification generally increases ODN potency, but in many instances it is associated with an increase of poorly understood nonspecific effects. In this study, we have found that both cellular retention and nonspecific protein binding are dependent upon the extent of the oligonucleotide's modification. Flow cytometry of cells treated with fluorescein-labeled single-stranded (ss) or double-stranded (ds) ODNs demonstrated that fully phosphorothioate-modified ODNs exhibit much greater cellular association than 3'-terminally modified ODNs (with three 3'-terminal phosphorothioate linkages). Additionally, gel shift assays with either ss- or ds-probes showed that fully phosphorothioate-modified ODNs also exhibit much greater cytoplasmic and nuclear protein binding than either 3'-terminally modified or unmodified ODNs. However, gel shift competition assays showed that transcription factor binding by fully phosphorothioate-modified ds-ODNs was completely nonspecific relative to 3'-terminally modified and unmodified ds-ODNs. These results suggest that the benefits derived from full phosphorothioate modification of ODNs may be negated by increases of nonspecific protein binding and associated sequence-independent effects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7929417

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  89 in total

Review 1.  The influence of base sequence on the immunostimulatory properties of DNA.

Authors:  D S Pisetsky
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides.

Authors:  P Lorenz; T Misteli; B F Baker; C F Bennett; D L Spector
Journal:  Nucleic Acids Res       Date:  2000-01-15       Impact factor: 16.971

3.  Selection of antisense oligodeoxynucleotides against glutathione S-transferase Mu.

Authors:  Peter A C 't Hoen; Ruud Out; Jan N M Commandeur; Nico P E Vermeulen; F H D van Batenburg; Muthiah Manoharan; Theo J C van Berkel; Erik A L Biessen; Martin K Bijsterbosch
Journal:  RNA       Date:  2002-12       Impact factor: 4.942

4.  A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices.

Authors:  Xiaohui Wei; Guowei Dai; Guido Marcucci; Zhongfa Liu; Dale Hoyt; William Blum; Kenneth K Chan
Journal:  Pharm Res       Date:  2006-05-25       Impact factor: 4.200

5.  In vivo delivery of antisense MORF oligomer by MORF/carrier streptavidin nanoparticles.

Authors:  Yi Wang; Xinrong Liu; Kayoko Nakamura; Ling Chen; Mary Rusckowski; Donald J Hnatowich
Journal:  Cancer Biother Radiopharm       Date:  2009-10       Impact factor: 3.099

6.  Sequence-independent inhibition of RNA transcription by DNA dumbbells and other decoys.

Authors:  C S Lim; N Jabrane-Ferrat; J D Fontes; H Okamoto; M R Garovoy; B M Peterlin; C A Hunt
Journal:  Nucleic Acids Res       Date:  1997-02-01       Impact factor: 16.971

7.  RNase H-independent antisense activity of oligonucleotide N3 '--> P5 ' phosphoramidates.

Authors:  O Heidenreich; S Gryaznov; M Nerenberg
Journal:  Nucleic Acids Res       Date:  1997-02-15       Impact factor: 16.971

Review 8.  Selective tissue targeting of synthetic nucleic acid drugs.

Authors:  Punit P Seth; Michael Tanowitz; C Frank Bennett
Journal:  J Clin Invest       Date:  2019-01-28       Impact factor: 14.808

9.  Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.

Authors:  Rosie Z Yu; Richard S Geary; Joann D Flaim; Gina C Riley; Diane L Tribble; André A vanVliet; Mark K Wedel
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 10.  Targeting ApoC-III to Reduce Coronary Disease Risk.

Authors:  Sumeet A Khetarpal; Arman Qamar; John S Millar; Daniel J Rader
Journal:  Curr Atheroscler Rep       Date:  2016-09       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.